

	L
nai	tera
110	CCIC

1234567-2-X
-------------

Accession ID# or MRN:

Please place collection kit

DATE OF SAMPLE COLLECTION	ON			1234567-2-X	barcode here.
PATIENT				1234301-2-1	
			ORDERING CLINICIAN	/ REPORT RECIPIENT	S
Patient Last Name	Patient First Name				
ratient Last Name	attent i ist warie				
Date of Birth (MM/DD/YY)	Cell Phone		Clinic or Organization		
Sale 6. S. a. (Min 25, 11.)			Enter or Check Clinicia	n Name Below	Phone
Patient Email			$\neg$		
		,	_		
Address			<b>□</b>		
	□ F	= 🔲 M 🦼			
City	State Zip Biolo	gical Sex			
PAYMENT INFORMATION					
	II Clinic / CA Prenatal Program PDC	Self Pay			
	ii Ciinic / C/(1 fenatar i fogram i De [				
land and the same of the same	Overver Niversia av		Additional Report Recipier	nt	Fax
Insurance Company	Group Number		STATEMENT OF MEDIC	CAL NECESSITY (REQUI	•
Marshau ID	Mariahan Maria				essary and this patient has been informed the risks, benefits, and alternatives, and
Member ID	Member Name				including NY CVR §79-I, as applicable.
Prior Authorization Number (If Applicable)	Compassionate Care Ref # (if Applie	rahle)			
Thorracion rambor (in Applicable)	Compassionate Caro Her II (II Applic	· · · · · · · ·	Ordering Clinician / Author	ized Signature	
PREGNANCY INFORMATION			FAMILY BACKGROUNI		
Is patient pregnant? 1st Trimester 2nd	d Trimester 3rd Trimester No	t pregnant	Personal / family history of	a genetic disorder (list sp	pecific conditions and person affected):
Expected Due Date (MM/DD/YY)	Patient Weight (lbs)	Ī	Patient ethnicity		
We do NOT accept vanishing twins, pregnancies v	with more than two fetuses OR egg dono	nijounioguico	☐ African American/Blac		nazi Jewish
with twins. For twin pregnancies or singleton egg of			<ul><li>☐ Hispanic/Latin Americ</li><li>☐ Mediterranean</li></ul>		dic Jewish
☐ <b>Twin pregnancy</b> ☐ Monochorionic ☐ <i>Twin Defaults to ICD O30.001-Twin pregnan</i>			<ul><li>☐ Mediterranean</li><li>☐ Caucasian/Non-Hispa</li></ul>		Canadan
sacs - first trimester. To use an alternat			HORIZON CARRIER S	CREEN (SEE DETAILS OF	N BACK)
☐ Surrogate or egg donor pregnancy Age of	genetic mother at egg retrieval:	,	0	,	
PANORAMA PRENATAL SCREEN (SEE DE	ETAILS ON BACK)				rmonal medications? Y N
<b>Panorama</b> □ Enroll patient in the	e Automatic Redraw Program (see	hack)		ct ONLY if no panels are ch	
☐ PANORAMA PRENATAL PANEL PLU		'	□ DMD □ CF □ SMA □ ADD Tay-Sachs Enzyme* (to any options or as single option) *Requires an additional blood tube when ordered; Saliva is not available for Enzyme		
Chromosomes 13, 18, 21, X and Y; 22q is not available for dizygotic twi	<b>Triploidy; 22q.11.2 deletion</b> ns or eaa donors.		PANEL OPTIONS	tube when ordered, canva is	not available for Enzyme
☐ I DO NOT want 22q.11.2			☐ <b>H4</b> SMA, CF, Fragile >		
☐ I <u>WANT</u> fetal sex reported ☐ <b>PANORAMA EXTENDED PANEL</b> (Not	t available for twins or egg donors)		H14 Pan-ethnic Standa	ra below, select H14 PLUS	add-on ontion below:
Panorama Prenatal Panel PLUS 5				nes for Pan-ethnic Mediur	
☐ I <u>WANT</u> fetal sex reported				nes for Comprehensive Je enes for Pan-ethnic Exten	
ICD-10 CODE (REQUIRED):	la 1at trimaatar		0		ked conditions; gene count will vary
<ul><li>☐ O09.511 Supervision of elderly primigravio</li><li>☐ O09.512 Supervision of elderly primigravio</li></ul>		l <sub>i</sub>	CD-10 CODE (REQUIRE	D):	
☐ 009.521 Supervision of elderly multigravid		1	☐ Z84.81 Family histor	ry of carrier of genetic dise	
<ul><li>☐ O09.522 Supervision of elderly multigravid</li><li>☐ Z34.81 Supervision of other normal preg</li></ul>	•			etic disease carrier status c disease carrier status for	for procreative management
☐ Z34.82 Supervision of other normal preg	nacy, 2nd trimester		•	ry of intellectual disabilities	
•	c finding on antenatal screening of mo	'		or genetic counseling	
Other ICD-10 Code (see back)		(	Other ICD-10 Code (see ba	ıck)	
VISTARA PRENATAL SCREEN (REQUIRE			<u> </u>		
	ogical parental samples are required and annot be performed for twin pregnancies of				al form.
ICD-10 CODE (REQUIRED):   © 028.3 Ultra	1 0			9	ICD-10 Code (see back)
PATIENT ACKNOWLEDGMENT					, , , , , , , , , , , , , , , , , , , ,
By my signature I acknowledge I have read an	nd agreed to the Patient Acknowledg	ment for testi	ng on the back page. New	York residents must chec	this box □ and sign below to permit
Natera to use their samples for research and de	evelopment; otherwise, their samples	will be discarde	ed within 60 days of testing	g. By providing the informati	tion included herein, I understand and
agree I may be contacted via, e.g., e-mail, or cell matters, and health-related products, services, o					
opt out at any time or by checking this box 🚨 🖡	Horizon patients: I would like to share	e my Horizon te			
Partner Name:		OB:			
Phone Number: (Fo			Patient Signature		Date
AUTHORIZATION TO RECEIVE INFORM					
I hereby authorize Natera or Cord Blood Reginal has an ongoing relationship. This authorization					

revocation. Any revocation of this authorization will not affect any use or disclosure made prior to receipt of the revocation. I understand that Natera / CBR will not condition my treatment, payment, enrollment or eligibility for benefits on this authorization. Patient Signature Date .

General Screening

Increased Risk

Abnormal Findings

Twin Pregnancy with unspecified number of placenta/amniotic sac - first trimester.....

Supervision of other normal pregnancy, 1st trimester 

Supervision of elderly primigravida, 2nd trimester.....

Supervision of elderly multigravida, 2nd trimester 

Encounter for other genetic testing of female for procreative management......Z31.438

Encounter for antenatal screening of mother.....

Supervision of elderly primigravida, 1st trimester......



### NOTE: ALL YELLOW FIELDS ON THE FRONT OF THIS FORM ARE REQUIRED



For test specifications, see www.panoramatest.com/panorama-test/test-specs

Patients must be at least 9 weeks gestation. 22q is not available for dizygoic twins or egg donors. Extended panel is not available for twins or egg donors.

Automatic Redraw Program: If this box is checked on the front of this form, and the patient receives a no result due to low fetal fraction or a laboratory processing issue, Natera will contact the patient on your behalf to schedule a redraw at no charge. This program is only available if this is the patient's first sample (not a redraw) and the patient's fetal fraction is greater than 2%. This program is not recommended for patients with a gestational age greater than or equal to 14 weeks, 0 days, and may not be available in all areas

#### TEST OPTIONS:

Panorama Prenatal Panel Plus 22q.11.2, Includes Zygosity Chromosomes 13, 18, 21, and X and Y; Triploidy; 22q.11.2 deletion syndrome

#### Panorama Extended Panel

Chromosomes 13, 18, 21, and X and Y; Triploidy; 22q.11.2 deletion syndrome, 1p36 deletion syndrome, Cri-du-chat syndrome, Angelman syndrome, and Prader-Willi syndrome

#### All Samples





Two 10mL Tiger-top Streck Cell-Free DNA BCT® blood tubes

Horizon™

For a complete list of diseases tested, see

www.horizonscreen.com

### GENES ANALYZED ON HORIZON PANELS

Horizon 3: CFTR, DMD, FMR1

Horizon 4: CFTR, DMD, FMR1, SMN1

Horizon 14: ACADM, ASPA, CFTR, DHCR7, DMD, FMR1, GALT, GBA, HBA1/HBA2, HBB, HEXA, IKBKAP, PKHD1, SMN1 \*NOTE: Saliva not available for H14

Horizon 27: Horizon 14 + 13 genes (ASS1, BLM, CLN3, G6PC, FAH, FANCC, IDUA, IVD,

MCOLN1, MMACHC, PEX1, PEX7, SMPD1)

**Horizon 106**: Horizon 14 + 92 genes, see www.horizonscreen.com Horizon 274: Horizon 14 + 260 genes, see www.horizonscreen.com

### If ordering Tay-Sachs (TSE)



One 10mL and one 6mL

Lavender-top BD Vacutainer K2 EDTA blood tube

### If NOT ordering TSE



One 10mL Lavender-top BD Vacutainer® K2 EDTA blood tube

OR One 2mL Oragene® saliva tube



For test specifications, see www.natera.com/vistara/conditions

This test is not recommended for patients who have been diagnosed with a genetic disorder on the panel

We recommend that samples be received in the lab within 72 hours after collection. Maternal samples received more than 5 days after date of collections will be rejected.

If the paternal sample is received more than 5 days after the maternal sample, the maternal and paternal samples will be rejected

## GENES ANALYZED ON VISTARA

### Craniosynostosis Syndromes

## **Noonan Spectrum Disorders**

BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, SHOC2, SOS1, SOS2, RAF1, RITI, PTPN11

### **Skeletal Disorders**

FGFR3, COL1A1, COL1A2

### Syndromic Disorders

JAG1, CHD7, HDAC8, NIPBL, RAD21, SMC1A, SMC3, TSC1, TSC2, NSD1, SYN-GAP1, CDKL5, MECP2

## Maternal Sample



Two 10mL Tiger-top Streck Cell-Free DNA BCT® blood tubes

# Paternal or Egg Donor Sample



One 6mL Lavender-top BD Vacutainer® K2 EDTA blood tube

(2mL Oragene® Saliva toocal alternative are optional on request)

# Conoral Caroonina

**Family History** 

General Screening	
Encounter for nonproductive screening for genetic disease carrier status	Z13.71
Screening for other disorder	Z13.8
Female for testing for genetic disease carrier status for procreative management	Z31.430
Male for testing for genetic disease carrier status for procreative management	Z31.440
Pregnant state, incidental	Z33.1
Supervision of normal 1st pregnancy, 1st trimester	Z34.01
Supervision of normal 1st pregnancy, 2nd trimester	Z34.02
Supervision of other normal pregnancy, 1st trimester	Z34.81
Supervision of normal pregnancy, unspecified trimester	Z34.91
Encounter for genetic counseling	Z31.5
Family History	
Family history of intellectual disabilities	Z81.0
Family history of other diseases of the musculoskeletal system and connective tissue	eZ82.69
Family history of carrier of genetic disease	
Family history of other specified conditions	Z84.89

### General Screening

Other mental disorders complicating pregnancy, 1st trimester	099.341
Other mental disorders complicating pregnancy, 2nd trimester	099.342
Other mental disorders complicating pregnancy, 3rd trimester	099.343
Encounter for antenatal screening of mother.	Z36.0
Increased Risk	
Supervision of elderly multigravida, 1st trimester	009.521
Supervision of elderly multigravida, 2nd trimester	009.522
Supervision of elderly primigravida, unspecified trimester	O09.519
Supervision of elderly multigravida, unspecified trimester	009.529
Supervision of other high risk pregnancies, 1st trimester	O09.891
Supervision of other high risk pregnancies, 2nd trimester	O09.892
Supervision of other high risk pregnancies, 3rd trimester	009.893
Supervision of other high risk pregnancies, unspecified trimester	O09.899
Abnormal Findings	
Other abnormal findings on antenatal screening of mother	028.1
Abnormal ultrasonic finding on antenatal screening of mother	
Abnormal radiologic finding on antenatal screening of mother	028.4
Abnormal chromosomal and genetic finding on antenatal screening of mother	028.5
Maternal care for (suspected) chromosomal abnormality in fetus, fetus 1	035.1XX1
Maternal care, other (suspected) fetal abnormality/damage, not applicable/unspecific	edO35.9XX0
Maternal care, other (suspected) fetal abnormality/damage, unspecified, fetus 1	035.0XX1
Family History	
Craniosyntosis	
Craniofacial dysostosis	Q75.1
Other congenital malformations of musculoskeletal system	Q79.8

Family history of carrier of genetic disease.....

### PATIENT ACKNOWLEDGMENT (READ AND SIGN THE FRONT OF THIS PAGE)

I have been informed of and understand the details of the tests ordered herein for me by my health care provider, including the risks, benefits and alternatives and I have consented to testing. I understand that the test results may inform me of a genetic condition that is present in myself or my partner that may require medical follow-up. I also understand that negative results do not rule out the possibility of a genetic condition in the fetus, myself and/or my partner. I authorize Natera or other provider to share the information on this form and my test results with my health insurer/health plan ("plan") on my behalf, with all benefits of my plan made payable directly to Natera or other provider. I understand that I am responsible for (a) costs not paid by my plan directly to Natera for tests ordered, including, without limitation, any copayments, deductibles, or amounts deemed 'patient responsibility' and (b) any amounts paid to me by my plan. This testing will not be covered by my plan if it is outside of the plan's coverage guidelines or deemed not medically necessary - (e.g. where prior authorization is required but not obtained) and I will be responsible for the cost of such testing between \$249 and \$1590 per test, discounts may apply. I assign to Natera the right to appeal on my behalf negative coverage decisions made by my plan and to assert all rights and claims reserved to me as the beneficiary thereof. I authorize Natera to charge my credit card for any balance I might owe with regard to my tests. The information obtained from my tests may be used in scientific publications or presentations, but my specific identity will not be revealed. Natera may contact my healthcare provider to obtain more information regarding clinical correlation and confirmatory testing. My leftover samples may be de-identified and used for research and development. I and my heirs will not receive payments, benefits, or rights to any resulting products or discoveries. If I do not want my samples used, I may send a request in writing to Natera Sample Retention Department at the address below within 60 days after test results have been issued and my samples will be destroyed.